[{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"MCLA-117","moa":"CLEC12A\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"MCLA-145","moa":"Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"MCLA-145","moa":"Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"MCLA-145","moa":"Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Incyte Corporation"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"MCLA-145","moa":"Co-stimulatory molecule 4-1BB (CD137)","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Petosemtamab","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Petosemtamab","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Merck & Co"},{"orgOrder":0,"company":"Merus","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Petosemtamab","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.40000000000000002,"dosageForm":"Infusion","sponsorNew":"Merus \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Jefferies"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Petosemtamab","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Petosemtamab","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.40000000000000002,"dosageForm":"Infusion","sponsorNew":"Merus \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Jefferies"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Petosemtamab","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.40000000000000002,"dosageForm":"Infusion","sponsorNew":"Merus \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Jefferies"},{"orgOrder":0,"company":"Merus","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.40000000000000002,"dosageForm":"Infusion","sponsorNew":"Merus \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Jefferies"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Petosemtamab","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Chiltern International Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Petosemtamab","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merus \/ Chiltern International Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Chiltern International Ltd"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"MCLA-158","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Partner Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"Zenocutuzumab","moa":"ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Partner Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merus \/ Partner Therapeutics"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Zenocutuzumab","moa":"ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Foundation Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Foundation Medicine"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"||ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Parsaclisib","moa":"||PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merus \/ Merus","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Merus"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Afatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merus","amount2":1.5800000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.5800000000000001,"dosageForm":"Undisclosed","sponsorNew":"Merus \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Merus \/ Gilead Sciences"},{"orgOrder":0,"company":"Merus","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merus \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Merus \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Merus","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merus","amount2":1.6599999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.6599999999999999,"dosageForm":"Undisclosed","sponsorNew":"Merus \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Merus \/ Eli Lilly"},{"orgOrder":0,"company":"Merus","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"Pembrolizumab","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":8,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":8,"dosageForm":"Infusion","sponsorNew":"Merus \/ Genmab","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Genmab"}]
Find Clinical Drug Pipeline Developments & Deals by Merus
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
